Tumor endothelial cells are targets for selective therapies: In vitro and in vivo models to evaluate antiangiogenic strategies

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3799-3807

  Dutour, A ^a   Rigaud, Michel ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Angiogenesis models; Angiogenic phenotype; Antiangiogenesis; Review; Tumor endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COMPLEMENTARY DNA; ENDOGLIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MATRIX METALLOPROTEINASE; TECHNETIUM 99M; TROPONIN I; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GROWTH INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LUNG CARCINOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCINTIANGIOGRAPHY; TUMOR CELL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27944459352     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Folkman J, Merler E, Abernathy C and Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
3. Folkman J: Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2: S127-133, 2003.
4. D'Amato RJ, Loughnan MS, Flynn E et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
5. Boehm T, Folkman J, Browder T et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
6. Cao Y: Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139-145, 2004.
7. Zhang X, Galardi E, Duquette M et al: Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 2337-2344, 2005.
8. Lee M, Ellis S and Eckhardt G: Integrating molecular oncology into clinical practice: antiangiogenic therapy. J Clin Oncol 23: 937-938, 2005.
9. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36, 1991.
10. St Croix B, Rago C, Velculescu V et al: Genes expressed in human tumor endothelium. Science 289: 1197-1202, 2000.
11. Augustin HG, Kozian DH and Johnson RC: Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cells phenotypes. Bioessays 16: 901-906, 1994.
12. Ran S and Thorpe PE: Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 54: 1479-1484, 2002.
13. Staton CA, Stribbling SM, Tazzyman S et al: Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 55: 233-248, 2004.
14. Dutour A, Monteil J, Paraf F et al: Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11: 311-319, 2005.
15. Dutour A, Rabinovich-Chable H, Kaletta C et al: Is troponin I gene therapy effective for osteosarcoma treatment? Study on a human-like orthotopic rat model. Anticancer Res 24: 3977-3982, 2004.
16. Ferrara N: VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
17. Klagsbrun M and Moses MA: Molecular angiogenesis. Chem Biol 6: R217-224, 1999.
18. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
19. Jain R: Molecular regulation of vessel maturation. Nature Med 9: 685-693, 2003.
20. Volm M, Mattern J and Koomagi R: Angiostatin expression in non-small cell lung cancer. Clin Cancer Res 6: 3236-3240; 2000.
21. Burrows FJ, Derbyshire J, Tazzari et al: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
22. Takahashi K, Mullinken JB, Kozakewich HPW et al: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93: 2357-2364, 1994.
23. Terman BI and Dougher-Vermazen M: Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev 15: 159-163, 1996.
24. Shalaby F, Ho J, Stanford WL et al: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89: 981-990, 1997.
25. Longo R, Sarmiento R, Fanelli B et al: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5: 237-256, 2002.
26. Gasparini G, Brooks PC, Biganzoli E et al: Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 4: 2625-2634, 1998.
27. Brooks PC, Silletti S, von Schalscha TL et al: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391-400, 1998.
28. Brooks PC, Stromblad S, Klemke R et al: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822, 1995.
29. Erdreich-Epstein A, Shimada H, Groshen S et al: Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60: 712-721, 2000.
30. Calderon RO and DeVries GH: Lipid composition and phospholipid asymmetry of membranes from a Schwann cell line. J Neurosci Res 49: 372-380, 1997.
31. Ran S, Downes A and Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62: 6132-6140, 2002.
32. Krasnici S, Werner A, Eichhorn ME et al: Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105: 561-567, 2003.
33. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
34. Jain RK: Delivery of molecular medicine to solid tumors. Science 271: 1079-1080, 1996.
35. Albo D, Wang TN and Tuszynski GP: Antiangiogenic therapy. Curr Pharm Des 10: 27-37, 2004.
36. Kerbel RS: Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19: 45s-51s, 2001.
37. Schmitt-Sody M, Strieth S, Krasnici S et al: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9: 2335-2341, 2003.
38. Yuan F, Leunig M, Huang SK et al: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356, 1994.
39. Thurston G, McLean JW, Rizen M et al: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101: 1401-1413, 1998.
40. Auerbach R, Lewis R, Shinners B et al: Angiogenesis assays: a critical overview. Clin Chem 49: 32-40, 2003.
41. Taraboletti G and Giavazzi R: Modelling approaches for angiogenesis. Eur J Cancer 40: 881-889, 2004.
42. Vailhe B, Vittet D and Feige JJ: In vitro models of vasculogenesis and angiogenesis. Lab Invest 81: 439-452, 2001.
43. Goldbrunner RH, Wagner S, Roosen K and Tonn JC: Models for assessment of angiogenesis in gliomas. J Neurooncol 50: 53-62, 2000.
44. Akhtar N, Dickerson EB and Auerbach R: The sponge Matrigel angiogenesis assay. Angiogenesis 5: 75-80, 2002.
45. Hasan J, Shnyder SD, Bibby M et al: Quantitative angiogenesis assays in vivo - a review. Angiogenesis 7: 1-16, 2004.
46. Schmedtje JF Jr, Ji YS, Liu WL et al: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997.
47. Ribeiro MJ, Phillips DJ, Benson JM et al: Hemostatic properties of the SV-40 transfected human microvascular endothelial cell line (HMEC-1). A representative in vitro model for microvascular endothelium. Thromb Res 79: 153-161, 1995.
48. Gagnon E, Cattaruzzi P, Griffith M et al: Human vascular endothelial cells with extended life spans: in vitro cell response, protein expression, and angiogenesis. Angiogenesis 5: 21-33, 2002.
49. Yang J, Chang E, Cherry AM et al: Human endothelial cell life extension by telomerase expression. J Biol Chem 274: 26141-26148, 1999.
50. Nisato RE, Harrison JA, Buser R et al: Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol 165: 11-24, 2004.
51. Auerbach R and Auerbach W: Assays to study angiogenesis. In: Tumor Angiogenesis and Microcirculation (Voest EE and D'Amore PA, eds.). New York: Marcel Dekker, pp. 91-102, 2001.
52. Staton CA, Stribbling SM, Tazzyman S et al: Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol 165: 11-24, 2004.
53. Lawley TJ and Kubota Y: Induction of morphologic differentiation of endothelial cells in culture. J Invest Dermatol 93: 59S-61S, 1989.
54. Benelli R and Albini A: In vitro models of angiogenesis: the use of Matrigel. Int J Biol Markers 14: 243-246, 1999.
55. Delves GH, Stewart AB, Lwaleed BA et al: In vitro inhibition of angiogenesis by prostasomes. Prostate Cancer Prostatic Dis 8: 174-178, 2005.
56. Huh JI, Calvo A, Stafford J et al: Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24: 790-800, 2005.
57. Nicosia RF, Bonanno E and Smith M: Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 154: 654-661, 1993.
58. Indraccolo S, Gola E, Rosato A et al: Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 9: 867-878, 2002.
59. Bergers G, Javaherian K, Lo KM et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812, 1999.
60. Stribbling SM, Friedlos F, Martin J et al: Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther 11: 285-292, 2000.
61. Tercel M, Stribbling SM, Sheppard H et al: Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores. J Med Chem 46: 2132-2151, 2003.
62. Staton CA, Brown NJ, Rodgers GR et al: Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103: 601-606, 2004.
63. Kuo CJ, Farnebo F, Yu EY et al: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98: 4605-10, 2001.
64. Li M, Huang X, Zhu Z et al: Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J Immunother 24: 472-81, 2001.
65. Osusky KL, Hallahan DE, Fu A et al: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7: 225-233, 2004.
66. Killion JJ, Radinsky R and Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metas Rev 17: 279-284, 1998.
67. Zhang ZL, Wang JH and Liu XY: Current strategies and future directions of antiangiogenic tumor therapy. Acta Biochemica et Biophysica Sinica 35: 873-880, 2003.
68. O'Reilly MS, Holmgren L, Shing Y et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
69. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. 2: 689-692, 1996.
70. Thierry JP, Perdereau B, Gorgora R et al: Un modèle expérimental d'ostéosarcome chez le rat: II L'ostéosarcome greffable du rat. Sem Hop Paris 25-29: 1684-1689, 1982.
71. Kruger EA, Duray PH, Price DK et al: Approaches to preclinical screening of antiangiogenic agents. Semin Oncol 28: 570-576, 2001.
72. Brenner W, Bohuslavizki KH and Eary JF: PET imaging of osteosarcoma. J Nucl Med 44: 930-942, 2003.
73. Siggelkow W, Zimmy M, Faridi A et al: The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23: 1859-1867, 2003.
74. Kerbel KS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.